CENTOGENE Announces Expansion of Data Access and Collaboration Agreement With Pfizer

Centogene N.V. a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced an expansion of the Company’s data access and collaboration agreement with Pfizer Inc. The initial agreement, which granted Pfizer access to data of interest from CENTOGENE’s Bio/Databank, was established in 2019 to advance the discovery and validation of novel genetic targets as candidates for the development of new therapies for rare diseases.

A new collaborative research project has now been initiated, which may be used to validate rare genetic causes of neurodegenerative diseases as potential targets for specific diseases. Data will be generated based on an existing cohort of patient samples from CENTOGENE’s Bio/Databank.

Dr. Patrice Denèfle, Chief Scientific Officer at CENTOGENE, said, “Establishing an additional collaborative research project with Pfizer underscores the value we believe our Bio/Databank may bring to data-driven discovery in rare diseases R&D. With our Bio/Databank, extensive cohorts from clinical studies, and diverse global diagnostic footprint, CENTOGENE is uniquely positioned to discover potential roadmaps for neurodegenerative diseases that may be linked to rare genetic factors. This new phase in our research collaboration project is a milestone achievement for innovative data-driven drug discovery and development that may help in delivering breakthrough treatments to patients.”

CENTOGENE’s unique Bio/Databank integrates relevant structured and unstructured patient-consented data, including clinical information, health records, and multiomic data, including genetic, transcriptomic, proteomic, and metabolomic insights. It also includes longitudinal data, such as biomarkers and patient recorded outcomes, as well as diagnostic workflow data. Individual-level data is managed, protected, and shared in compliance with international data privacy regulations.